Cue Biopharma is trading 6.4% up at $40.27 after B. Riley initiated coverage on September 18, 2026, with a Buy rating and an $83.00 price target, citing potential in CUE-221.
- The analyst highlighted encouraging chronic-hives data and upcoming Phase 2 results.
- The move extends a strong multi-session rally, with broader biotech strength providing additional sector support.